Supplementary Table 2. Patient demographics, baseline characteristics and clinical response by analysis set

Metric[*]	Full Randomized Set		Biomarker Analysis Set		RNA-Seq Analysis Set[^]		P-value[+]	
	Placebo (n=44)	Filgotinib (n=130)	Placebo (n=42)	Filgotinib (n=126)	Placebo (n=29)	Filgotinib (n=72)	Placebo	Filgotinib
Age	33 [27, 41]	36 [29, 44]	32 [27, 41]	36 [29, 42]	34 [28, 41]	36 [29, 42]	0.987	0.994
Sex (%)	M 41%, F 59%	M 45%, F 55%	M 41%, F 59%	M 44%, F 56%	M 31%, F 69%	M 43%, F 57%	0.651	0.950
Exposed to anti-TNF-a, n(%)	28 (64%)	77 (59%)	26 (62%)	73 (58%)	18 (62%)	37 (51%)	0.984	0.540
Oral corticosteroids use, n(%)	23 (52%)	65 (50%)	22 (52%)	65 (52%)	17 (61%)	33 (46%)	0.660	0.735
CRP (mg/L)	8.1 [3.6, 23.9]	8.2 [3.1, 16.9]	9.0 [3.6, 25.4]	8.2 [3.0, 17.1]	5.3 [2.7, 11.7]	8.2 [2.7, 16.8]	0.643	0.755
CRP>10mg/L, n(%)	20 (45%)	53 (41%)	20 (48%)	51 (41%)	9 (31%)	28 (39%)	0.339	0.964
Disease duration (years)	5.4 [3.1, 10.2]	6.2 [3.2, 11.5]	5.4 [3.3, 10.3]	6.2 [3.0, 11.5]	5.7 [2.2, 10.2]	6.2 [3.1, 13.0]	0.999	0.998
SES-CD	14 [10, 21]	12 [10, 19]	15 [11, 22]	12 [10, 19]	15 [12, 21]	12 [10, 19]	0.919	0.931
Endoscopic response, n(%)	6 (17%)	32 (31%)	6 (18%)	31 (30%)	4 (14%)	23 (33%)	0.913	0.908

*Values are median [Q1, Q3] unless otherwise stated.

^64 patients included in the biomarker analysis set were not included in the RNA-Seq analysis set due to lack of sample availability. A further three patient samples were removed due to the data quality control checks.

+P-values were generated by comparing means of the three placebo data sets and comparing means of the three filgotinib data sets. One-way ANOVA was used for continuous variables and Chi-Square test was used for categorial variables